Cost-effectiveness of using etanercept as first Line in severe and highly active rheumatoid Arthritis (ra)
Year of publication: |
2008-11
|
---|---|
Authors: | Le Pen, Claude ; Miadi-Fargier, H. ; Fautrel, B. ; Maravic, M. ; Daures, JP. ; Ollivier, AL. ; Maurel, F. |
Institutions: | Université Paris-Dauphine (Paris IX) |
Subject: | Health expenditures | Health care | Drugs | Pharmaceutical industry |
-
Verteporfin in neovascular amd : real life confirms Clinical trials results
Le Pen, Claude, (2009)
-
Does pharmaceutical consumption improve health care Status ?
Amalric, F., (2009)
-
The Economics behind the Epidemic: Afghan Opium Price and Prescription Opioids in the US
Deiana, Claudio, (2019)
- More ...
-
Impact of rheumatoid arthritis (ra) on working conditions and income
Le Pen, Claude, (2009)
-
Feneron, D., (2008)
-
Indirect costs of rheumatoid arthritis and their Determinants
Le Pen, Claude, (2009)
- More ...